Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orthofix Medical Inc. filings document regulatory disclosures for a medical technology company focused on spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales, guidance-related exhibits and non-GAAP measures including constant currency, free cash flow, adjusted gross profit and adjusted margin.
The company’s proxy and governance filings cover director elections, executive compensation, equity award disclosures, auditor ratification and common-share voting matters. Other current reports document Spine leadership changes, annual meeting results and board committee appointments.
Orthofix Medical Inc. is updating its outlook after Medicare reimbursement changes for non-invasive bone growth stimulators. Following an FDA reclassification of these devices to Class II and related CMS billing updates effective May 18, 2026, the company expects average Medicare reimbursement for key HCPCS codes to decline by about 10%.
Orthofix now projects full-year 2026 net sales of $838–$848 million and non-GAAP adjusted EBITDA of $90–$93 million, and it does not expect positive free cash flow for 2026. The company has withdrawn its three-year financial targets and will continue assessing the long-term effects of current and future CMS actions.
Orthofix Medical Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,700,000 shares of common stock, representing 6.73% of the class as reported in Amendment No. 7 to a Schedule 13G/A. The filing states Armistice Capital exercises voting and investment power over the shares held by Armistice Capital Master Fund Ltd., and Mr. Boyd, as managing member, may be deemed to beneficially own those securities.
Orthofix Medical Inc. director John B. Henneman III made an open-market purchase of 5,000 shares of common stock at $12.259 per share. Following this transaction, he holds 90,809 shares directly, which the footnote explains includes 48,347 deferred stock units and 2,103 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. shareholder entities associated with Engine Capital reported open-market purchases of the company’s common stock. Engine Capital, L.P. and Engine Lift Capital, LP together bought 184,896 shares between May 5 and May 7, 2026 at prices around $11.99–$12.23 per share. These shares are held indirectly through the Engine investment funds, and the reporting persons expressly limit beneficial ownership to their respective pecuniary interests. One filing line also updates that Engine Jet Capital, L.P. holds 344,652 shares of Orthofix common stock.
Orthofix Medical Inc. reported first-quarter 2026 results that show modest growth and improved bottom-line performance while reaffirming its full-year outlook. Reported net sales were $196.7 million, up 1.6% year over year, with non-GAAP pro forma net sales of $196.4 million, up 2.7% on a constant currency basis as spine distributor transitions tapered off.
Global Spine Fixation grew 6% and Therapeutic Solutions grew 5% year over year on a constant currency basis, while Global Limb Reconstruction net sales rose 3%. GAAP net loss narrowed to $20.9 million, or $(0.52) per share, compared with a net loss of $53.1 million, or $(1.35) per share, a year earlier.
Non-GAAP pro forma adjusted EBITDA was $9.7 million, or 4.9% of pro forma net sales, versus $11.4 million, or 6.0%, reflecting geography mix and commercial transitions. Cash, cash equivalents, and restricted cash increased to $120.9 million as of March 31, 2026, helped by financing activities, while free cash flow was negative $28.3 million. The company reaffirmed 2026 guidance for net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive full-year free cash flow excluding any potential legal settlements.
Orthofix Medical Inc. is asking shareholders to vote at its June 10, 2026 annual meeting on four items: electing ten directors, approving 2025 executive pay on an advisory basis, ratifying EY as auditor for 2026, and approving Amendment No. 5 to its stock purchase plan.
For 2025, Orthofix reported net sales of $822.3 million and a reported net loss of $(92.2) million, while non-GAAP pro forma adjusted EBITDA reached $85.9 million, or 10.6% of non-GAAP pro forma net sales. Free cash flow was $3.1 million excluding M6-related restructuring charges.
The Board highlights strong support for its pay practices, with about 98% of votes cast backing the 2025 say-on-pay proposal and at least 90% support in each of the last ten years. Most CEO and named executive officer pay is performance-based, and all directors except the CEO are independent under Nasdaq rules.
Orthofix Medical Inc. CLO Jorge Andres Cedron reported an open-market sale of 3,743 shares of common stock at $12.82 per share on April 16, 2026. According to the footnote, these shares were sold solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, Compensation and Talent Development Committee–mandated sell-to-cover requirement, leaving the executive with 59,006 shares, including 44,353 previously reported restricted stock units. The sale was made without any exercise of discretion by the reporting person.
Orthofix Medical Inc. reported preliminary first quarter 2026 net sales of approximately $196.7 million, with non-GAAP pro forma net sales of about $196.4 million, reflecting 0.4% reported growth and 3% constant currency pro forma growth versus Q1 2025. The company reaffirmed its 2026 outlook, guiding full-year net sales between $850 million and $860 million, implying about 5.5% pro forma constant currency growth at the midpoint, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow excluding potential legal settlements. Orthofix also announced a strategic realignment of its Spine leadership, eliminating the President, Global Spine Solutions role so key spine leaders now report directly to the CEO, and disclosed that President, Global Spine Max Reinhardt will depart around June 12, 2026, with severance benefits under his existing agreement.
Orthofix Medical Inc Schedule 13G/A discloses that The Vanguard Group reports 0 shares beneficially owned and 0% of the class for Orthofix common stock following an internal realignment. The filing cites an internal reorganization effective January 12, 2026 and is signed on 03/27/2026.